Medicines for Malaria Venture (MMV), Genzyme Corp. (Nasdaq: GENZ), and the Broad Institute of MIT and Harvard have recently agreed to expand their collaboration in order to discover and advance new therapeutic candidates for malaria.
The said alliance will build on earlier work this year and will enable the expansion of a drug discovery program focused on identifying compounds that may offer a completely new approach in the treatment of malaria.
According to Dr. Chris Hentschel, president and CEO of MMV:
"We are very pleased to expand our support for what has already begun to be a productive collaboration between one of the premier genomic research institutions and one of the world's leading biotechnology companies.
This collaboration enhances our capacity to identify promising new antimalarial compounds and explore completely novel approaches to treat this deadly disease."
The announcement of this expanded collaboration have been announced in Abu Dhabi, United Arab Emirates, following a presentation made by representatives of Genzyme and the Broad Institute to MMV's board of directors and representatives of the Abu Dhabi Bio City project.
Find more details from the MMV press release.
Comment Preview